Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
Status:
Completed
Trial end date:
2014-04-17
Target enrollment:
Participant gender:
Summary
After transplantation, renal impairment, incidence and progression of atherosclerosis lead to
modification of immunosuppressive regimens, as switch, reduction or discontinuation of CNI
and/or introduction of everolimus. The risk or benefits of these strategies were not clearly
evaluated by specific clinical trials.
This study is specifically designed for evaluating the impact of everolimus introduction,
with calcineurin dose reduction, at less one year after cardiac transplantation, on renal and
clinical outcomes, specially on :
- Renal function improvement
- Vasculopathy and major cardiac event reduction
- Maintenance of immunosuppressive efficacy